-
5 Drug Companies Profiting From Generics
Monday, August 4, 2014 - 8:29am | 864Read More...Leading generic drug maker Teva Pharmaceutical (NYSE: TEVA) posted better than expected earnings last week and raised its full-year profit forecast. There was plenty for investors to be concerned about, though. Sales of its best-selling product, Copaxone, were down for the quarter, and activist...
-
UPDATE: Piper Jaffray Color on Akorn Initiation
Monday, June 6, 2011 - 7:42am | 188Read More...Piper Jaffray, which initiated coverage of Akorn (NASDAQ: AKRX), is providing some color on the stock. “We are initiating coverage of Akorn, Inc. with an Overweight rating and $10 price target,” Piper Jaffray writes. “Akorn's expanding generics portfolio, mainly focused on ophthalmics and...
-
Piper Jaffray Initiates Akorn At Overweight, $10 PT
Monday, June 6, 2011 - 6:06am | 25Read More...Piper Jaffray has initiated coverage on Akorn, Inc. (NASDAQ: AKRX) with an Overweight rating and $10 price target.
